Interview with Ralf Vayntrub, Founder & President, Invar
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Address: 2 Ploshchad Zhuravleva, bld.2, 107023 Moscow,Russia
Tel: +7 (495) 962-16-62
Web: http://www.invarpharma.com/
INVAR is the Russian, privately-owned, national pharmaceutical & biotechnology company forming a product portfolio on the basis of
long-term exclusive in-licensing or distribution agreements on marketing and sales for the Russian market with owners of innovative medicines.
Number of employees – 104
Activity areas: Gynecology and Obstetrics, Dermatology, Otolaryngology, Pediatrics
Areas of interest: Innovative original pharmaceuticals, preferably in the spheres of dermatology, gynecology, otorhinolaryngology (ENT) and pediatrics
Company geography: Representation in 15 key regions of the Russia
Our dedicated team performs all key business processes:
• Regulatory & Clinical Affairs
• Marketing
• Sales Forces Organization
• Logistics & Supply Chain
• Commercial Operations
Products: Fluomizin, Gynoflor E (Medinova, Switzerland), Sinuforte (Hartington S.L., Spain), Epigen (Cheminova S.A., Spain), Skin Cap (Cheminova S.A., Spain)
Services: Registration, promotion and distribution of innovative pharmaceutical products within the territory of the Russia
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here